Search research articles
Contact Us
Filters
Showing results (21-30 of 45) with videos related to
Page
of 5
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society
|
June 1, 2000
Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson's disease
H H Fernandez, M C Lannon, J H Friedman, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
December 19, 2001
Predictors of depressive symptoms among spouse caregivers in Parkinson's disease
H H Fernandez, R E Tabamo, R R David, et al.
Neurology
|
June 6, 2007
Is decreased dexterity in Parkinson disease due to apraxia?
K Heilman, K Quencer, M S Okun, et al.
Neurology
|
December 8, 2006
Limb-kinetic apraxia in Parkinson disease
K Quencer, M S Okun, G Crucian, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research
|
November 1, 2001
Is altropane SPECT more sensitive to fluoroDOPA PET for detecting early Parkinson's disease?
H H Fernandez, J H Friedman, A J Fischman, et al.
Parkinsonism & Related Disorders
|
July 21, 2009
Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial
H H Fernandez, D R Greeley, R M Zweig, et al.
The International Journal of Neuroscience
|
October 20, 2012
Is 6 months of neuroleptic withdrawal sufficient to distinguish drug-induced parkinsonism from Parkinson's disease?
T T Lim, A Ahmed, I Itin, et al.
Neurology
|
July 13, 2006
Dissociating apathy and depression in Parkinson disease
L Kirsch-Darrow, H H Fernandez, H F Fernandez, et al.
Journal of Clinical Pharmacology
|
August 10, 2000
Variable absorption of carbidopa affects both peripheral and central levodopa metabolism
R Durso, J E Evans, E Josephs, et al.
Parkinsonism & Related Disorders
|
December 29, 2024
Duration of "Good On" time per dose: Immediate-release carbidopa-levodopa vs. extended-release carbidopa-levodopa (IPX203, CREXONT®)
R A Hauser, H H Fernandez, J Jimenez-Shahed, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 45) with videos related to
Sort By:
Page
of 5
Movement Disorders : Official Journal of the Movement Disorder Society
|
June 1, 2000
Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson's disease
H H Fernandez, M C Lannon, J H Friedman, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
December 19, 2001
Predictors of depressive symptoms among spouse caregivers in Parkinson's disease
H H Fernandez, R E Tabamo, R R David, et al.
Neurology
|
June 6, 2007
Is decreased dexterity in Parkinson disease due to apraxia?
K Heilman, K Quencer, M S Okun, et al.
Neurology
|
December 8, 2006
Limb-kinetic apraxia in Parkinson disease
K Quencer, M S Okun, G Crucian, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research
|
November 1, 2001
Is altropane SPECT more sensitive to fluoroDOPA PET for detecting early Parkinson's disease?
H H Fernandez, J H Friedman, A J Fischman, et al.
Parkinsonism & Related Disorders
|
July 21, 2009
Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial
H H Fernandez, D R Greeley, R M Zweig, et al.
The International Journal of Neuroscience
|
October 20, 2012
Is 6 months of neuroleptic withdrawal sufficient to distinguish drug-induced parkinsonism from Parkinson's disease?
T T Lim, A Ahmed, I Itin, et al.
Neurology
|
July 13, 2006
Dissociating apathy and depression in Parkinson disease
L Kirsch-Darrow, H H Fernandez, H F Fernandez, et al.
Journal of Clinical Pharmacology
|
August 10, 2000
Variable absorption of carbidopa affects both peripheral and central levodopa metabolism
R Durso, J E Evans, E Josephs, et al.
Parkinsonism & Related Disorders
|
December 29, 2024
Duration of "Good On" time per dose: Immediate-release carbidopa-levodopa vs. extended-release carbidopa-levodopa (IPX203, CREXONT®)
R A Hauser, H H Fernandez, J Jimenez-Shahed, et al.
Page
of 5